Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 16/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2577500 | 0.88 | GHSR (0.76) | GHSR | |
| SCHEMBL6176255 | 0.87 | GHSR (0.73) | GHSR | |
| SCHEMBL2581006 | 0.87 | GHSR (0.69) | GHSR | |
| SCHEMBL2576235 | 0.86 | GHSR (0.69) | GHSR | |
| SCHEMBL6179340 | 0.85 | GHSR (0.70) | GHSR | |
| SCHEMBL6179342 | 0.85 | GHSR (0.66) | GHSROPRM1OPRL1P2RX7 | |
| SCHEMBL2577096 | 0.85 | GHSR (0.66) | GHSR | |
| SCHEMBL18488452 | 0.84 | GHSR (0.85) | GHSRP2RX7 | |
| SCHEMBL2581081 | 0.84 | GHSR (0.65) | GHSRP2RX7 | |
| SCHEMBL6179306 | 0.84 | GHSR (0.65) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389941-A1 | Growth-hormone secretagogues | Elixir Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20080261873-A1 | Growth-Hormone Secretagogues | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1781311-A2 | GROWTH-HORMONE SECRETAGOGUES | Elixir Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006023608-A2 | GROWTH-HORMONE SECRETAGOGUES | ELIXIR PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1105376-B1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMA (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-6576656-B1 | Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261873-A1 | Growth-Hormone Secretagogues | GHSR, GHRHR, GIPR | GHSR 1/4885NPSR1 153/4885OPRM1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.